• Strategic alliances to expedite further growth of healthcare services portfolio
  • Addition of Diagnostics Facility to service ongoing requirements for PCR and related testing
  • Strengthening of resources to enable full-scale delivery of healthcare digitisation projects

Kuala Lumpur: 07 March 2022 – Technology group OMESTI Berhad (OMESTI) is further expanding its portfolio of healthcare services with the formation of two strategic joint venture companies (JVC), leveraging the Group’s digitisation track record.

A JVC has been established with Medical Innovation Ventures Sdn Bhd (Mediven®) for the purpose of setting up and operating a diagnostics and test laboratory, for conducting, amongst others, PCR (Polymerase Chain Reaction) testing used in the definitive detection of coronavirus infections. The first laboratory, to be located in Penang, will be operated on behalf of the JVC by Mediven® technicians, and backed by Mediven’s comprehensive diagnostics technology and expertise. 

The second JVC has been established with Tree Med Sdn Bhd (Tree Med/TMSB), a company which is engaged in the supply of medical and laboratory equipment. The JVC is being formed for the purpose of collaboration in healthcare projects which includes amongst others participating and bidding in tenders issued by the healthcare sector. The delivery of such projects will utilise resources pooled from both JVC parties.

Gerard Monteiro, Executive Director of OMESTI Berhad, said, “These new joint ventures represent an important initiative on our part to expand our healthcare portfolio in line with our overall growth strategy. The JVCs will be able to leverage the considerable expertise and resources of Mediven® and Tree Med, combined with our own technology expertise and increase our footprint in the healthcare sector.”

These latest initiatives follow on from the earlier investment of RM15.8 million by OMESTI in the Bemed Group of companies, which added trading and retail sale of pharmaceutical products, orthopaedic and medical goods, perfumery products, cosmetics and toiletries to its portfolio. These activities are in addition to the sales and distribution of COVID-19 vaccines and Rapid Test-Kits already being handled by OMESTI.

OMESTI’s technology expertise and track record will lead to the full digitisation of its healthcare operations, putting the patient and consumer at the heart of the ecosystem. This digital ecosystem, which will be rolled out in phases, will span the entire medical requirements chain with services ranging from e-consultations with medical professionals to diagnosis, through to prescription issue and fulfilment, follow-up consultation and purchase of general medical supplies via the Group’s digital pharmacy portal.

About Mediven®

Medical Innovation Ventures Sdn. Bhd. (Mediven®) is a medical diagnostic company which develops, manufactures, and markets advanced high quality clinical diagnostic molecular and rapid tests. Mediven® provides solutions for screening of a variety of infectious diseases including coronavirus, dengue, chikungunya, zika, malaria, influenza, tuberculosis and many more. 

Mediven® production facilities comply with ISO 13485:2016 and its products are compliant with EU relevant legislation on safety, health & environmental requirements, allowing the sales of products under the CE Mark within the European Economic Area. Mediven® also holds a medical device production licence from the Malaysian Medical Authority (MDA) and the Good Distribution Practice for Medical Devices (GDPMD) certification.

About Tree Med Tree Med is engaged in the distribution of microbiology products, bench top chemistry analysers, laboratory consumables supplies, and distribution of third-party reagents and parts for haematology and histology. It also supplies other products related to laboratory operations including medical grade centrifuges, fridges, and freezers etc. Included in its portfolio is a wide range of Blood Bank products, including: instruments and consumables for screening and confirmation of Blood Viruses (HIV, Hepatitis, Syphilis); distribution of Immunohaematology automation and consumables for blood grouping, antibody screening, and cross-matching purposes; distribution of HLA typing, HLA antibody screening and ID, Platelet antibody ID, HPA typing; Cord Blood bank instruments and consumables;